The Inflammatory Heart Diseases: Causes, Symptoms, and Treatments

[1]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[2]  L. Mosca.  C-reactive protein--to screen or not to screen? , 2002, The New England journal of medicine.

[3]  M. Hiroe,et al.  Tenascin‐C is a useful marker for disease activity in myocarditis , 2002, The Journal of pathology.

[4]  Katsuhiko Yano,et al.  C-reactive protein and myocardial infarction. , 2002, Journal of clinical epidemiology.

[5]  J. Plutzky.  Inflammatory pathways in atherosclerosis and acute coronary syndromes. , 2001, The American journal of cardiology.

[6]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[7]  Philip Greenland,et al.  Prevention Conference V Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Executive Summary , 2000 .

[8]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[9]  P. Libby,et al.  Novel inflammatory markers of coronary risk: theory versus practice. , 1999, Circulation.

[10]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[11]  R. Tracy.  Inflammation in cardiovascular disease: cart, horse, or both? , 1998, Circulation.

[12]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[13]  P C Elwood,et al.  Fibrinogen, Viscosity, and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1991, Circulation.

[14]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[15]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[16]  Deepak L. Bhatt,et al.  Acute pericarditis: appendicitis of the heart? , 2009, Mayo Clinic proceedings.

[17]  K. Kleesiek,et al.  Lipopolysaccharide-binding protein: a new biomarker for infectious endocarditis? , 2009, Clinical chemistry.

[18]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[19]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.